{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:11:39Z","timestamp":1791220299637,"version":"4.1.0"},"reference-count":267,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hypertension is a frequent comorbidity of obesity that significantly and independently increases the risk of cardiovascular and renal events. Obesity-related hypertension is a major challenge to the healthcare system because of the rapid increase in obesity prevalence worldwide. However, its treatment is still not specifically addressed by current guidelines. Weight loss (WL) per se reduces blood pressure (BP) and increases patient responsiveness to BP-lowering medications. Thus, a weight-centric approach is essential for the treatment of obesity-related hypertension.<\/jats:p>\n                  <jats:p>Diet and physical activity are key components of lifestyle interventions for obesity-related hypertension, but, in real life, their efficacy is limited by poor long-term patient adherence and frequently require pharmacotherapy implementation to achieve target BP. In this context, first-generation anti-obesity drugs such as orlistat, phentermine\/topiramate, and naltrexone\/bupropion are poorly effective, whereas second-generation incretin receptor agonists, including the GLP-1 receptor agonists liraglutide and semaglutide, and in particular the dual GLP-1\/glucose-dependent insulinotropic polypeptide (GIP) co-agonist tirzepatide, substantially contribute to effective WL and BP control in obesity. SGLT2 inhibitors are weak body weight and BP-lowering medications, but clearly synergize the benefits of these medications. Bariatric surgery remains the gold standard treatment for severe \u201cpathological\u201d obesity and related life-threatening complications. Renal denervation is a valuable rescue treatment for drug-resistant hypertension, commonly related to obesity.<\/jats:p>\n                  <jats:p>Integrating a multifaceted weight-based approach with other strategies, such as antihypertensive drugs and renal denervation, could specifically target the main neuro-hormonal and renal pathophysiological mechanisms of obesity-related hypertension, including sympathetic-nervous and renin\u2013angiotensin\u2013aldosterone systems overactivity, salt retention, and volume expansion. This comprehensive strategy can provide a personalized algorithm for managing hypertension in obesity within the context of \u201cprecision medicine\u201d principles.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf035","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:32:01Z","timestamp":1739172721000},"source":"Crossref","is-referenced-by-count":14,"title":["Mechanisms and treatment of obesity-related hypertension\u2014Part 2: Treatments"],"prefix":"10.1093","volume":"18","author":[{"given":"Aneliya","family":"Parvanova","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Clinical Research Centre for Rare Diseases \u201cAldo e Cele Dacc\u00f2\u201d: Istituto di Ricerche Farmacologiche Mario Negri IRCCS , Ranica, Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Abbate","sequence":"additional","affiliation":[{"name":"Research Group on Global Health, University of the Balearic Islands, and Research Group on Nursing, Community & Global Health, Health Research Institute of the Balearic Islands (IdISBa) , both in Palma ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Reseghetti","sequence":"additional","affiliation":[{"name":"Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Clinical Research Centre for Rare Diseases \u201cAldo e Cele Dacc\u00f2\u201d: Istituto di Ricerche Farmacologiche Mario Negri IRCCS , Ranica, Bergamo ,","place":["Italy"]},{"name":"Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"2025032505180320100_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025032505180320100_bib2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"2025032505180320100_bib3"},{"key":"2025032505180320100_bib4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/erv.2861","article-title":"Effects of COVID-19 lockdown on eating disorders and obesity: a systematic review and meta-analysis","volume":"29","author":"Sideli","year":"2021","journal-title":"European Eating Disord Rev"},{"key":"2025032505180320100_bib5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/oby.23662","article-title":"The COVID-19 lockdown increased obesity disparities; will the increases in type 2 diabetes continue?","volume":"31","author":"Dietz","year":"2023","journal-title":"Obesity"},{"key":"2025032505180320100_bib6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2025032505180320100_bib7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ Res"},{"key":"2025032505180320100_bib8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","article-title":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis","volume":"398","author":"Nazarzadeh","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025032505180320100_bib12","volume-title":"Guideline for the Pharmacological Treatment of Hypertension in Adults [Internet]","year":"2021"},{"key":"2025032505180320100_bib13","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"SPRINT Research Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamacardio.2022.3345","article-title":"Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jaeger","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025032505180320100_bib15","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41371-021-00630-4","article-title":"Is it time to reconsider the treatment paradigm for obese patients with hypertension?","volume":"36","author":"Kennedy","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2025032505180320100_bib17","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2025032505180320100_bib18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13181-015-0488-6","article-title":"A review of the toxicologic implications of obesity","volume":"11","author":"Zuckerman","year":"2015","journal-title":"J Med Toxicol"},{"key":"2025032505180320100_bib19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2025032505180320100_bib20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000446862","article-title":"Obesity, renin-angiotensin system blockade and risk of adverse renal outcomes: a population-based cohort study","volume":"43","author":"Cohen","year":"2016","journal-title":"Am J Nephrol"},{"key":"2025032505180320100_bib21","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/01.HYP.0000190819.07663.da","article-title":"Body mass index and angiotensin-dependent control of the renal circulation in healthy humans","volume":"46","author":"Ahmed","year":"2005","journal-title":"Hypertension"},{"key":"2025032505180320100_bib22","doi-asserted-by":"publisher","first-page":"sfad282","DOI":"10.1093\/ckj\/sfad282","article-title":"Mechanisms and treatment of obesity-related hypertension\u2014part 1: mechanisms","volume":"17","author":"Parvanova","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025032505180320100_bib23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573396318666220801093225","article-title":"Childhood obesity: an updated review","volume":"20","author":"Leung","year":"2024","journal-title":"Curr Ped Rev"},{"key":"2025032505180320100_bib24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obesity Rep"},{"key":"2025032505180320100_bib25","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","article-title":"Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association","volume":"78","author":"Hall","year":"2021","journal-title":"Hypertension"},{"key":"2025032505180320100_bib26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity"},{"key":"2025032505180320100_bib27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000445504","article-title":"Effect of a modest weight loss in normalizing blood pressure in obese subjects on antihypertensive drugs","volume":"9","author":"Gilardini","year":"2016","journal-title":"Obesity Facts"},{"key":"2025032505180320100_bib28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ajh\/hpab162","article-title":"Cost-effectiveness of recommendations from the Surgeon General's call-to-action to control hypertension","volume":"35","author":"Tajeu","year":"2022","journal-title":"Am J Hypertens"},{"key":"2025032505180320100_bib29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1291\/hypres.25.881","article-title":"Relationship between changes in serum leptin levels and blood pressure after weight loss","volume":"25","author":"Itoh","year":"2002","journal-title":"Hypertension Res"},{"key":"2025032505180320100_bib30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/ijo.2010.171","article-title":"The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women","volume":"35","author":"Harvie","year":"2011","journal-title":"Int J Obesity"},{"key":"2025032505180320100_bib31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pcad.2013.09.003","article-title":"Impact of obesity and weight loss on cardiac performance and morphology in adults","volume":"56","author":"Alpert","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"key":"2025032505180320100_bib32","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3390\/nu11071667","article-title":"Weight loss and hypertension in obese subjects","volume":"11","author":"Fantin","year":"2019","journal-title":"Nutrients"},{"key":"2025032505180320100_bib33","doi-asserted-by":"publisher","first-page":"e228212","DOI":"10.1001\/jamanetworkopen.2022.8212","article-title":"Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial","volume":"5","author":"Carneiro-Barrera","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025032505180320100_bib34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/cts.13241","article-title":"Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: systematic review and meta-analysis","volume":"15","author":"Kov\u00e1cs","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025032505180320100_bib35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2337\/dc16-0509","article-title":"Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the action for health in diabetes (Look AHEAD) clinical trial","volume":"39","author":"The Action for Health in Diabetes (Look AHEAD) Study Group","year":"2016","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib36","first-page":"S90","article-title":"Precision medicine and therapies of the future","volume":"62 Suppl 2","author":"Sisodiya","year":"2021","journal-title":"Epilepsia"},{"key":"2025032505180320100_bib37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/164_2021_566","article-title":"Precision medicine and obesity","volume":"274","author":"Sacoto","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"2025032505180320100_bib38","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1161\/HYPERTENSIONAHA.123.21710","article-title":"Precision hypertension","volume":"81","author":"Dzau","year":"2024","journal-title":"Hypertension"},{"key":"2025032505180320100_bib39","doi-asserted-by":"publisher","first-page":"e016804","DOI":"10.1161\/JAHA.120.016804","article-title":"Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension","volume":"9","author":"Fu","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025032505180320100_bib40","doi-asserted-by":"publisher","first-page":"750714","DOI":"10.3389\/fcvm.2021.750714","article-title":"Effects of intermittent compared with continuous energy restriction on blood pressure control in overweight and obese patients with hypertension","volume":"8","author":"He","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025032505180320100_bib41","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1016\/j.numecd.2021.05.030","article-title":"The effects of the Dietary Approaches to stop hypertension (DASH) diet on metabolic risk factors in patients with chronic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Lari","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025032505180320100_bib42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/met.2010.0031","article-title":"Mediterranean diet and weight loss: meta-analysis of randomized controlled trials","volume":"9","author":"Esposito","year":"2011","journal-title":"Metab Syndr Relat Disord"},{"key":"2025032505180320100_bib43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/HYPERTENSIONAHA.115.06853","article-title":"Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials","volume":"67","author":"Gay","year":"2016","journal-title":"Hypertension"},{"key":"2025032505180320100_bib44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE Study","volume":"170","author":"Blumenthal","year":"2010","journal-title":"Arch Intern Med"},{"key":"2025032505180320100_bib45","first-page":"CD009825","article-title":"Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Rees","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032505180320100_bib46","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/ajcn\/nqy384","article-title":"Dose-response relation between dietary sodium and blood pressure: a meta-regression analysis of 133 randomized controlled trials","volume":"109","author":"Graudal","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"2025032505180320100_bib47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.pcad.2020.08.001","article-title":"Special article\u2014the management of resistant hypertension: a 2020 update","volume":"63","author":"Carey","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2025032505180320100_bib48","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/CIRCULATIONAHA.120.050371","article-title":"Blood pressure effects of sodium reduction: dose\u2013response meta-analysis of experimental studies","volume":"143","author":"Filippini","year":"2021","journal-title":"Circulation"},{"key":"2025032505180320100_bib49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/HJH.0000000000002604","article-title":"The effect of plant-based dietary patterns on blood pressure: a systematic review and meta-analysis of controlled intervention trials","volume":"39","author":"Gibbs","year":"2021","journal-title":"J Hypertens"},{"key":"2025032505180320100_bib50","doi-asserted-by":"publisher","first-page":"e015719","DOI":"10.1161\/JAHA.119.015719","article-title":"Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials","volume":"9","author":"Filippini","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025032505180320100_bib51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.ajkd.2016.03.431","article-title":"Urine potassium excretion, kidney failure, and mortality in CKD","volume":"69","author":"Leonberg-Yoo","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025032505180320100_bib52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1475-2891-11-105","article-title":"Whey protein and essential amino acids promote the reduction of adipose tissue and increased muscle protein synthesis during caloric restriction-induced weight loss in elderly, obese individuals","volume":"11","author":"Coker","year":"2012","journal-title":"Nutr J"},{"key":"2025032505180320100_bib53","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/07315724.2004.10719381","article-title":"The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review","volume":"23","author":"Halton","year":"2004","journal-title":"J Am Coll Nutr"},{"key":"2025032505180320100_bib54","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.clnu.2019.08.008","article-title":"Effects of high-protein diet on glycemic control, insulin resistance and blood pressure in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Yu","year":"2020","journal-title":"Clin Nutr"},{"key":"2025032505180320100_bib55","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.numecd.2014.04.011","article-title":"Breaking up prolonged sitting reduces resting blood pressure in overweight\/obese adults","volume":"24","author":"Larsen","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025032505180320100_bib56","doi-asserted-by":"publisher","first-page":"e243234","DOI":"10.1001\/jamanetworkopen.2024.3234","article-title":"Sitting time reduction and blood pressure in older adults: a randomized clinical trial","volume":"7","author":"Rosenberg","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025032505180320100_bib57","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.116.08994","article-title":"Dose\u2013response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Liu","year":"2017","journal-title":"Hypertension"},{"key":"2025032505180320100_bib58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11906-020-01087-5","article-title":"The role of exercise in patients with obesity and hypertension","volume":"22","author":"Keating","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"2025032505180320100_bib59","doi-asserted-by":"publisher","first-page":"e13269","DOI":"10.1111\/obr.13269","article-title":"Effect of exercise on cardiometabolic health of adults with overweight or obesity: focus on blood pressure, insulin resistance, and intrahepatic fat\u2014a systematic review and meta-analysis","volume":"22","author":"Battista","year":"2021","journal-title":"Obes Rev"},{"key":"2025032505180320100_bib60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/10998004211015424","article-title":"What types of exercise are more effective in reducing obesity and blood pressure for middle-aged women? A systematic review with meta-analysis","volume":"23","author":"Park","year":"2021","journal-title":"Biol Res Nurs"},{"key":"2025032505180320100_bib61","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/02640414.2020.1766178","article-title":"The effect of low-volume high-intensity interval training on cardiometabolic health and psychological responses in overweight\/obese middle-aged men","volume":"38","author":"Poon","year":"2020","journal-title":"J Sports Sci"},{"key":"2025032505180320100_bib62","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/dc23-2448","article-title":"Timing of moderate to vigorous physical activity, mortality, cardiovascular disease, and microvascular disease in adults with obesity","volume":"47","author":"Sabag","year":"2024","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib63","first-page":"CD008823","article-title":"Walking for hypertension","volume":"2","author":"Lee","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032505180320100_bib64","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","article-title":"World Health Organization 2020 guidelines on physical activity and sedentary behaviour","volume":"54","author":"Bull","year":"2020","journal-title":"Br J Sports Med"},{"key":"2025032505180320100_bib65","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1161\/CIRCULATIONAHA.121.055329","article-title":"Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial","volume":"144","author":"Blumenthal","year":"2021","journal-title":"Circulation"},{"key":"2025032505180320100_bib66","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12872-024-03746-w","article-title":"Effect of mindfulness-based interventions on people with prehypertension or hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2025032505180320100_bib67","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1001\/jama.2015.16303","article-title":"CPAP vs mandibular advancement devices and blood pressure in patients with obstructive sleep apnea: a systematic review and meta-analysis","volume":"314","author":"Bratton","year":"2015","journal-title":"JAMA"},{"key":"2025032505180320100_bib68","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","article-title":"The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis","volume":"2","author":"Roerecke","year":"2017","journal-title":"Lancet PubHealth"},{"key":"2025032505180320100_bib69","first-page":"1","article-title":"Smoking cessation decreases arterial blood pressure in hypertensive smokers: a subgroup analysis of the randomized controlled trial GENTSMOKING","volume":"22","author":"Gaya","year":"2024","journal-title":"Tobacco Induced Dis"},{"key":"2025032505180320100_bib70","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/ijo.2015.96","article-title":"Association between eating rate and obesity: a systematic review and meta-analysis","volume":"39","author":"Ohkuma","year":"2015","journal-title":"Int J Obes"},{"key":"2025032505180320100_bib71","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1038\/s41467-023-43444-3","article-title":"Dietary circadian rhythms and cardiovascular disease risk in the prospective NutriNet-Sant\u00e9 cohort","volume":"14","author":"Palomar-Cros","year":"2023","journal-title":"Nat Commun"},{"key":"2025032505180320100_bib72","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/jocn.16033","article-title":"Adherence to lifestyle modifications and its associated factors in hypertensive patients","volume":"31","author":"Dhakal","year":"2022","journal-title":"J Clin Nurs"},{"key":"2025032505180320100_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.7408","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated systematic review for the U.S. Preventive Services Task Force [Internet]","author":"Patnode","year":"2022"},{"key":"2025032505180320100_bib74","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/jama.2020.21749","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force Recommendation Statement","volume":"324","author":"US Preventive Services Task Force","year":"2020","journal-title":"JAMA"},{"key":"2025032505180320100_bib75","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amepre.2018.06.028","article-title":"Results from a trial of an online diabetes prevention program intervention","volume":"55","author":"Moin","year":"2018","journal-title":"Am J Prev Med"},{"key":"2025032505180320100_bib76","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1111\/dom.15919","article-title":"An internet-based platform with a low-calorie dietary intervention improves cardiometabolic risk factors in overweight and obese people in China: half-year follow-up results of a randomized controlled trial","volume":"26","author":"Zhong","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib77","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS Guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"2025032505180320100_bib78","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity"},{"key":"2025032505180320100_bib79","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11906-019-0915-1","article-title":"Weight loss medications in the treatment of obesity and hypertension","volume":"21","author":"Cohen","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"2025032505180320100_bib80","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity"},{"key":"2025032505180320100_bib81","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fendo.2019.00883","article-title":"Cardiovascular risks and benefits of medications used for weight loss","volume":"10","author":"Bramante","year":"2020","journal-title":"Front Endocrinol"},{"key":"2025032505180320100_bib82","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obesity"},{"key":"2025032505180320100_bib83","first-page":"CD007654","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","volume":"1","author":"Siebenhofer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025032505180320100_bib84","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41371-021-00644-y","article-title":"Highlights of mechanisms and treatment of obesity-related hypertension","volume":"36","author":"Shams","year":"2022","journal-title":"J Hum Hypertens"},{"key":"2025032505180320100_bib85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib86","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","author":"van Bloemendaal","year":"2014","journal-title":"J Endocrinol"},{"key":"2025032505180320100_bib87","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"2025032505180320100_bib88","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obesity Rev"},{"key":"2025032505180320100_bib89","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib90","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025032505180320100_bib91","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"2025032505180320100_bib92","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032505180320100_bib93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"Controlled trial of 3.0\u00a0mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib94","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib95","article-title":"FDA approves weight management drug for patients aged 12 and older","author":"U.S. Food and Drug Administration","year":"2021","journal-title":"FDA"},{"key":"2025032505180320100_bib96","article-title":"FDA approves new drug treatment for chronic weight management, first since 2014 [Internet]","author":"U.S. Food and Drug Administration","year":"2021","journal-title":"FDA"},{"key":"2025032505180320100_bib97","author":"Saxenda | European Medicines Agency (EMA) [Internet]","year":"2015"},{"key":"2025032505180320100_bib98","author":"Wegovy | European Medicines Agency (EMA) [Internet]","year":"2022"},{"key":"2025032505180320100_bib99","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10641963.2019.1676771","article-title":"Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"42","author":"Zhao","year":"2020","journal-title":"Clin Exp Hypertens"},{"key":"2025032505180320100_bib100","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib101","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-week randomized controlled trial of Semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without Metformin","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Endocrine Disord"},{"key":"2025032505180320100_bib103","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3803\/EnM.2020.934","article-title":"Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials","volume":"36","author":"Moon","year":"2021","journal-title":"Endocrinol Metab"},{"key":"2025032505180320100_bib104","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/jcm11112998","article-title":"Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Barboza","year":"2022","journal-title":"J Clin Med"},{"key":"2025032505180320100_bib105","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"key":"2025032505180320100_bib106","doi-asserted-by":"publisher","first-page":"935823","DOI":"10.3389\/fphar.2022.935823","article-title":"Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Gao","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025032505180320100_bib107","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/01.hjh.0000938980.77721.18","article-title":"The effects of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"41","author":"Kennedy","year":"2023","journal-title":"J Hypertens"},{"key":"2025032505180320100_bib108","doi-asserted-by":"publisher","first-page":"e3680","DOI":"10.1002\/dmrr.3680","article-title":"Effects of treatment with glucagon-like peptide-1 receptor agonist on prediabetes with overweight\/obesity: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"2025032505180320100_bib109","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib110","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocrine Pract"},{"key":"2025032505180320100_bib111","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression","volume":"26","author":"Rivera","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"2025032505180320100_bib112","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","article-title":"Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials","volume":"43","author":"Wong","year":"2025","journal-title":"J Hypertens"},{"key":"2025032505180320100_bib113","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2025032505180320100_bib114","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2025032505180320100_bib115","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/03007995.2024.2383731","article-title":"Evaluating the safety profile of semaglutide: an updated meta-analysis","volume":"40","author":"Rivera","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"2025032505180320100_bib116","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41366-024-01526-2","article-title":"Effect of combined GLP-1 analogue and bupropion\/naltrexone on weight loss: a retrospective cohort study","volume":"48","author":"Naude","year":"2024","journal-title":"Int J Obesity"},{"key":"2025032505180320100_bib117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025032505180320100_bib118","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","article-title":"Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials","volume":"28","author":"Fonseca","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2025032505180320100_bib119","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obesity"},{"key":"2025032505180320100_bib120","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3390\/life12081222","article-title":"The case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome","volume":"12","author":"Sultana","year":"2022","journal-title":"Life"},{"key":"2025032505180320100_bib121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/pharmacy12010011","article-title":"The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review","volume":"12","author":"Le","year":"2024","journal-title":"Pharmacy"},{"key":"2025032505180320100_bib122","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr Opin Pharmacol"},{"key":"2025032505180320100_bib123","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib124","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"2025032505180320100_bib125","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ehjcvp\/pvad097","article-title":"The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease","volume":"10","author":"Lincoff","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025032505180320100_bib126","doi-asserted-by":"publisher","first-page":"102060","DOI":"10.1016\/j.cpcardiol.2023.102060","article-title":"Obesity, cardiovascular disease, and the promising role of Semaglutide: insights from the SELECT trial","volume":"49","author":"Irfan","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2025032505180320100_bib127","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib128","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib129","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2025032505180320100_bib130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032505180320100_bib131","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41366-023-01456-5","article-title":"Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study","volume":"48","author":"Ghusn","year":"2024","journal-title":"Int J Obes"},{"key":"2025032505180320100_bib132","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimer's Dementia"},{"key":"2025032505180320100_bib133","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(21)00340-9","article-title":"The link between blood pressure and Alzheimer's disease","volume":"20","author":"DeCarli","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025032505180320100_bib134","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib135","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"2025032505180320100_bib136","article-title":"Side effects of GLP-1 drugs: what doctors should know [Internet]"},{"key":"2025032505180320100_bib137","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"2025032505180320100_bib138","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"2025032505180320100_bib139","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025032505180320100_bib140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/dom.15292","article-title":"Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"26","author":"Bea","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib141","year":"2023"},{"key":"2025032505180320100_bib142","article-title":"No increased risk for thyroid cancer in diabetic patients prescribed GLP-1 medications compared to those prescribed insulin [Internet]","volume-title":"Epic Res","author":"RN"},{"key":"2025032505180320100_bib143"},{"key":"2025032505180320100_bib144","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP1 receptor agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatrics"},{"key":"2025032505180320100_bib145","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2025032505180320100_bib146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"2025032505180320100_bib147","article-title":"FDA updates GLP-1 label with pulmonary aspiration warning [Internet]"},{"key":"2025032505180320100_bib148","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13741-024-00439-y","article-title":"The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","volume":"13","author":"do Nascimento","year":"2024","journal-title":"Periop Med"},{"key":"2025032505180320100_bib149","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2025032505180320100_bib150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib151","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"2025032505180320100_bib152","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/XCS.0000000000001157","article-title":"Bariatric and foregut","volume":"239","author":"Cunningham","year":"2024","journal-title":". J Am Coll Surgeons"},{"key":"2025032505180320100_bib153","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(24)01356-4","article-title":"International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches","volume":"404","author":"Dellgren","year":"2024","journal-title":"Lancet"},{"key":"2025032505180320100_bib154","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2025032505180320100_bib155","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2005","journal-title":"Int J Obes"},{"key":"2025032505180320100_bib156","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"2025032505180320100_bib157","article-title":"FDA approves new medication for chronic weight management [Internet]","author":"U.S. Food and Drug Administration","year":"2024","journal-title":"FDA"},{"key":"2025032505180320100_bib158","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7570\/jomes22012","article-title":"The upcoming weekly tides (semaglutide vs. tirzepatide) against obesity: STEP or SURPASS?","volume":"31","author":"Jung","year":"2022","journal-title":"J Obesity Metab Syndr"},{"key":"2025032505180320100_bib159","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib160","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib161","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2025032505180320100_bib162","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib163","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/DMSO.S443396","article-title":"The effect of tirzepatide on weight, lipid metabolism and blood pressure in overweight\/obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"17","author":"Lv","year":"2024","journal-title":"Diabetes Metab Syndr Obesity Targets Ther"},{"key":"2025032505180320100_bib164","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejim.2023.04.005","article-title":"Tirzepatide decreases systolic and diastolic blood pressure","volume":"114","author":"Copur","year":"2023","journal-title":"Eur J Internal Med"},{"key":"2025032505180320100_bib165","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025032505180320100_bib166","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obesity Metab"},{"key":"2025032505180320100_bib167","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527\u00a0kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"key":"2025032505180320100_bib168","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2025032505180320100_bib169","doi-asserted-by":"publisher","first-page":"NEJMoa2404881","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib170","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"2025032505180320100_bib171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"2025032505180320100_bib172","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib173","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032505180320100_bib174","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib175","doi-asserted-by":"publisher","first-page":"110729","DOI":"10.1016\/j.diabres.2023.110729","article-title":"MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and \u201cpreserved\u201d kidney function: a cross-sectional study","volume":"201","author":"Parvanova","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025032505180320100_bib176","doi-asserted-by":"publisher","first-page":"e3810","DOI":"10.1002\/dmrr.3810","article-title":"MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: a cross-sectional population study","volume":"40","author":"Abbate","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"2025032505180320100_bib177","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2025032505180320100_bib178","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2025032505180320100_bib179","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib180","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"2025032505180320100_bib181","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/dom.15342","article-title":"Impact of a dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: a systematic review and pairwise and network meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib182","doi-asserted-by":"publisher","first-page":"NEJMoa2410819","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","author":"Jastreboff","year":"2024","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib183","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.15148","article-title":"Tirzepatide 10 and 15\u00a0mg compared with semaglutide 2.4\u00a0mg for the treatment of obesity: an indirect treatment comparison","volume":"25","author":"Le Roux","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib184","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025032505180320100_bib185","article-title":"Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial [Internet]","author":"Wingrove","year":"2024","journal-title":"Reuters"},{"key":"2025032505180320100_bib186","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib187","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/dom.14979","article-title":"Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0\u2009mg for the management of type 2 diabetes in the United States","volume":"25","author":"Valentine","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib188","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib189","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib190","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib191","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/dom.14794","article-title":"In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist","volume":"24","author":"Jones","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib192","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025032505180320100_bib193","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib194","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib195","first-page":"313","article-title":"Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes","volume":"5","author":"Kim","year":"2012","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"2025032505180320100_bib196","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity"},{"key":"2025032505180320100_bib197","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025032505180320100_bib198","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025032505180320100_bib199","doi-asserted-by":"publisher","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025032505180320100_bib200","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.eprac.2024.03.001","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on the 24-hour ambulatory blood pressure in patients with type 2 diabetes mellitus and hypertension: an updated meta-analysis","volume":"30","author":"Iqbal","year":"2024","journal-title":"Endocrine Pract"},{"key":"2025032505180320100_bib201","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of Canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"2025032505180320100_bib202","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","article-title":"Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"33","author":"Ferreira","year":"2020","journal-title":"Am J Hypertens"},{"key":"2025032505180320100_bib203","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"2025032505180320100_bib204","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41440-023-01464-y","article-title":"Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"47","author":"Tsukamoto","year":"2024","journal-title":"Hypertens Res"},{"key":"2025032505180320100_bib205","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2025032505180320100_bib206","doi-asserted-by":"publisher","first-page":"204062232210835","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther Adv Chron Dis"},{"key":"2025032505180320100_bib207","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025032505180320100_bib208","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib209","doi-asserted-by":"publisher","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"2025032505180320100_bib210","doi-asserted-by":"crossref","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"2025032505180320100_bib211","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2025032505180320100_bib212","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"2025032505180320100_bib213","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity"},{"key":"2025032505180320100_bib214","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding","volume":"29","author":"O'Brien","year":"2019","journal-title":"Obes Surg"},{"key":"2025032505180320100_bib215","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/dom.15117","article-title":"Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: a meta-analysis and network meta-analysis of randomized controlled trials","volume":"25","author":"De Luca","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib216","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa1700459","article-title":"Weight and metabolic outcomes 12 years after gastric bypass","volume":"377","author":"Adams","year":"2017","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib217","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"2025032505180320100_bib218","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174\u2009772 participants","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet"},{"key":"2025032505180320100_bib219","doi-asserted-by":"publisher","first-page":"e1003206","DOI":"10.1371\/journal.pmed.1003206","article-title":"Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis","volume":"17","author":"Wiggins","year":"2020","journal-title":"PLoS Med"},{"key":"2025032505180320100_bib220","doi-asserted-by":"publisher","first-page":"e13670","DOI":"10.1111\/obr.13670","article-title":"Association of bariatric surgery with indicated and unintended outcomes: an umbrella review and meta-analysis for risk-benefit assessment","volume":"25","author":"Kim","year":"2024","journal-title":"Obes Rev"},{"key":"2025032505180320100_bib221","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1177\/1060028014529260","article-title":"Effect of bariatric surgery on hypertension: a meta-analysis","volume":"48","author":"Wilhelm","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2025032505180320100_bib222","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension)","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"key":"2025032505180320100_bib223","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jacc.2023.11.032","article-title":"Randomized trial of effect of bariatric surgery on blood pressure after 5 years","volume":"83","author":"Schiavon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025032505180320100_bib224","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-3781","article-title":"Three-year outcomes of bariatric surgery in patients with obesity and hypertension\u202f: a randomized clinical trial","volume":"173","author":"Schiavon","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025032505180320100_bib225","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s11695-023-06711-2","article-title":"Shorter history of hypertension as a predictor of hypertension remission after 3-years of bariatric surgery: data from the GATEWAY trial","volume":"33","author":"Oliveira","year":"2023","journal-title":"Obes Surg"},{"key":"2025032505180320100_bib226","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.physbeh.2009.03.012","article-title":"Metabolic surgery and gut hormones\u2014a review of bariatric entero-humoral modulation","volume":"97","author":"Ashrafian","year":"2009","journal-title":"Physiol Behav"},{"key":"2025032505180320100_bib227","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/00031348231220576","article-title":"Updates in bariatric surgery","volume":"90","author":"Hsu","year":"2024","journal-title":"Am Surg"},{"key":"2025032505180320100_bib228","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"2025032505180320100_bib229","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1007\/s00464-023-10387-1","article-title":"Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study","volume":"37","author":"Ilanga","year":"2023","journal-title":"Surg Endosc"},{"key":"2025032505180320100_bib230","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11695-020-04850-4","article-title":"Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study","volume":"31","author":"Thakur","year":"2021","journal-title":"Obes Surg"},{"key":"2025032505180320100_bib231","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes Surg"},{"key":"2025032505180320100_bib232","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care\u2014a systematic overview of international evidence-based guidelines","volume":"20","author":"Semlitsch","year":"2019","journal-title":"Obes Rev"},{"key":"2025032505180320100_bib233","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000665","article-title":"Emerging therapies for treatment-resistant hypertension: a review of Lorundrostat and related selective aldosterone synthase inhibitors","author":"Feldman","year":"2024","journal-title":"Cardiol Rev"},{"key":"2025032505180320100_bib234","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/10641963.2015.1131290","article-title":"Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea","volume":"38","author":"Yang","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"2025032505180320100_bib235","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5664\/jcsm.6054","article-title":"Effect of antihypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis","volume":"12","author":"Khurshid","year":"2016","journal-title":"J Clin Sleep Med"},{"key":"2025032505180320100_bib236","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"2025032505180320100_bib237","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with Lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2025032505180320100_bib238","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib239","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"key":"2025032505180320100_bib240","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"2025032505180320100_bib241","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14712598.2024.2425343","article-title":"Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?","volume":"24","author":"Doggrell","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"2025032505180320100_bib242","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib243","article-title":"FDA Roundup: November 14, 2023 [Internet]","author":"U.S. Food and Drug Administration","year":"2024","journal-title":"FDA"},{"key":"2025032505180320100_bib244","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.122.20503","article-title":"Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis","volume":"80","author":"Biffi","year":"2023","journal-title":"Hypertension"},{"key":"2025032505180320100_bib245","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.jacc.2021.04.044","article-title":"Changes in plasma renin activity after renal artery sympathetic denervation","volume":"77","author":"Mahfoud","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025032505180320100_bib246","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"2025032505180320100_bib247","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"2025032505180320100_bib248","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamacardio.2023.0338","article-title":"Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials","volume":"8","author":"Kirtane","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025032505180320100_bib249","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib250","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","article-title":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial","volume":"399","author":"Mahfoud","year":"2022","journal-title":"Lancet"},{"key":"2025032505180320100_bib251","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730","article-title":"Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study","volume":"142","author":"Kario","year":"2020","journal-title":"Circulation"},{"key":"2025032505180320100_bib252","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(23)00733-X","article-title":"Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients","volume":"401","author":"Staplin","year":"2023","journal-title":"Lancet"},{"key":"2025032505180320100_bib253","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1097\/HJH.0000000000001798","article-title":"Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis","volume":"36","author":"Kordalis","year":"2018","journal-title":"J Hypertens"},{"key":"2025032505180320100_bib254","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1161\/CIRCULATIONAHA.123.066941","article-title":"Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure 6 months after medication escalation: the RADIANCE Clinical Trial Program","volume":"149","author":"Azizi","year":"2024","journal-title":"Circulation"},{"key":"2025032505180320100_bib255","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ccd.29884","article-title":"Renal denervation in hypertension patients: proceedings from an expert consensus roundtable cosponsored by SCAI and NKF","volume":"98","author":"Kandzari","year":"2021","journal-title":"Catheter Cardiovasc Intervent"},{"key":"2025032505180320100_bib256","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur Heart J"},{"key":"2025032505180320100_bib257","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025032505180320100_bib258","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib259","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.15077","article-title":"New insights into the treatment of obesity","volume":"25","author":"Bl\u00fcher","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025032505180320100_bib260","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"2025032505180320100_bib261","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejim.2023.12.022","article-title":"Effect of tirzepatide on blood pressure levels in overweight\/obese individuals without diabetes","volume":"121","author":"Patoulias","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025032505180320100_bib262","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14656566.2018.1458092","article-title":"Pharmacotherapeutic strategies for treating hypertension in patients with obesity","volume":"19","author":"Carnagarin","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2025032505180320100_bib263","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40256-019-00393-x","article-title":"Effects of blood pressure lowering agents on cardiovascular outcomes in weight excess patients: a systematic review and meta-analysis","volume":"20","author":"Francischetti","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025032505180320100_bib264","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025032505180320100_bib265","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"2025032505180320100_bib266","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2025032505180320100_bib267","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf035\/61851367\/sfaf035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/3\/sfaf035\/61851367\/sfaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/3\/sfaf035\/61851367\/sfaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:46:57Z","timestamp":1743212817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf035\/8009105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":267,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf035","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,11]]},"article-number":"sfaf035"}}